The clinical significance of somatic BRCA1/2 mutations in breast cancer remains inconclusive, and the ongoing NCT03344965 and VIOLETTE (NCT03330847) trials are designed to answer the question whether BRCA1/2 somatic mutation could act as a predictive marker for the PARP inhibitor olaparib response as in ovarian cancer [38]. This evidence concerns the gene BRCA1 and breast carcinoma.